Analyzing 2seventy bio (TSVT) & The Competition

2seventy bio (NASDAQ:TSVTGet Rating) is one of 948 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare 2seventy bio to similar companies based on the strength of its earnings, profitability, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation & Earnings

This table compares 2seventy bio and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
2seventy bio $54.52 million -$292.21 million -1.52
2seventy bio Competitors $1.84 billion $246.51 million -4.27

2seventy bio’s peers have higher revenue and earnings than 2seventy bio. 2seventy bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

91.5% of 2seventy bio shares are held by institutional investors. Comparatively, 42.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 2.5% of 2seventy bio shares are held by insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for 2seventy bio and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
2seventy bio 0 0 5 0 3.00
2seventy bio Competitors 3066 12981 39137 629 2.67

2seventy bio currently has a consensus target price of $29.75, suggesting a potential upside of 89.37%. As a group, “Pharmaceutical preparations” companies have a potential upside of 89.16%. Given 2seventy bio’s stronger consensus rating and higher possible upside, equities research analysts clearly believe 2seventy bio is more favorable than its peers.

Profitability

This table compares 2seventy bio and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
2seventy bio -496.68% -100.76% -43.84%
2seventy bio Competitors -3,226.41% -161.16% -24.40%

Summary

2seventy bio beats its peers on 7 of the 12 factors compared.

2seventy bio Company Profile

(Get Rating)

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.